Exhibit 99.1
For Immediate Release
Novadaq Reports First Quarter 2012 Financial Results
Toronto, Ontario—May 4, 2012 — Novadaq® Technologies Inc. (“Novadaq” or the “Company”) (NASDAQ: NVDQ, TSX: NDQ,), a developer of clinically-relevant fluorescence imaging solutions for use in surgical procedures, today announced financial results for its first quarter ended March 31, 2012. Unless otherwise indicated, all dollar amounts in this press release are expressed in United States (U.S.) dollars.
“We are focused on building a sustainable business model based on partnering our SPY fluorescence imaging technology for certain surgical applications with market leading companies and commercializing, on our own, new systems such as PINPOINT® for endoscopic surgery”, commented Dr. Arun Menawat, Novadaq’s President and CEO.
“The combined installed base of SPY technology in the United States now exceeds 400 systems, and 3,100 open SPY procedure kits were shipped during the first quarter of 2012, increasing SPY recurring revenues by 180% year-over-year. Additionally, with the recent completion of the $40.3 million equity financing, and by sponsoring a multi-center clinical trial called PILLAR™, we have taken the initial steps towards the commercialization of PINPOINT,” added Dr. Menawat.
First Quarter Corporate Highlights
| | • | | Novadaq shipped 120 SPYElite® and FIREFLY systems during the first quarter. At March 31, 2012, the number of US hospitals with installed SPY and FIREFLY systems exceeded 400. |
| | • | | 3,100 SPY kits for open surgical procedures were shipped to hospitals during the first quarter, representing a 163% increase over the same period in 2011, and a 15% sequential increase compared with Q4-2011. |
| | • | | In January, Novadaq named MAQUET Cardiovascular as the exclusive US distributor of Novadaq’s CO2 Heart Laser products. |
| | • | | In March, Novadaq announced that its common shares were approved for listing on the NASDAQ Global Market (NASDAQ) under the ticker symbol “NVDQ.” |
| | • | | Also in March, the Company announced that the Centers for Medicare & Medicaid Services established SPY Vascular Angiography as a new reimbursable service under the Hospital Outpatient Prospective Payment System, effective April 1, 2012. |
| | • | | Prior to the end of the quarter, Novadaq initiated the multi-center PILLAR (Perfusion Assessment in Laparoscopic Left Anterior Resection) clinical trial, which will study the use of PINPOINT endoscopic fluorescence imaging in up to 150 patients undergoing laparoscopic left colectomies. Details of the study can be found at:www.clinicaltrials.gov, searching identifier NCT01560377. |
Financial Highlights
| | • | | Total revenues in the first quarter were $4.8 million, a 103% increase compared to $2.3 million in the same period in 2011, due mainly to increased sales of systems and procedure kits across both of our commercial SPY businesses (SPYElite and FIREFLY). Total revenues decreased sequentially by $228,000 in comparison to Q4-2011 due to seasonality in SPYElite capital sales, and lower TMR revenues. |
Novadaq Reports First Quarter 2012 Financial Results
| | • | | First quarter recurring revenues for our SPY businesses totaled $2.1 million, representing year-over-year growth of 180% compared to Q1-2011, and sequential growth of 16% compared to Q4-2011. |
| | • | | Operating burn (cash used in operating activities before changes in working capital) was close to break-even at $0.08 million in the first quarter. Excluding the impact of NASDAQ registration fees, operations would have contributed $0.2 million. This compares with operating burns of $1.8 million for the same period in 2011, and $0.03 million in Q4-2011. Working capital contributed $0.6 million during the first quarter 2012, and $1.9 million was invested, including $1.8 million to build the SPY Elite installed base. |
| | • | | At March 31, 2012, cash and cash equivalents totaled $7.9 million, and 32.8 million basic shares were outstanding. Subsequent to the end of the quarter, the Company raised $40.3 million by way of an underwritten equity offering (net proceeds approximately $36.9 million), issuing 7,015,000 shares at a price of $5.75 per share. |
Conference Call
Novadaq is pleased to invite all interested parties to participate in a conference call today, Friday, May 4, 2012, at 8:30 a.m. Eastern Time during which the results will be discussed.
Those wishing to access the live conference call by telephone should dial 1-877-407-8031 (within Canada and the United States) or 1-201-689-8031 (international callers) several minutes prior to the beginning of the call. A telephonic replay of the conference call will be made available until midnight on June 4, 2012 and can be accessed by dialing 1-877-660-6853 (within Canada and the United States) or 1-201-612-7415 (international callers) and entering the account number 286 and the conference identification number 388170 when prompted.
The call will be archived for 90 days on the Company’s website at http://www.novadaq.com under the “Events” tab in the Investors section. In addition, a replay of the call will be available for download to a portable audio player or computer, as an MP3 or podcast file, at the same location on Novadaq’s website.
About Novadaq Technologies Inc.
Enabling surgeons with clinically-relevant, innovative fluorescence imaging solutions to enhance the lives of patients and their surgeons, while reducing health care costs, is Novadaq’s global mission. SPY fluorescence imaging technology provides surgeons with real-time visualization, leading to improved outcomes and reduced costs without exposing the patient to radiation. More than 50 peer-reviewed publications demonstrate that the use of SPY during complex surgery, leads to fewer post-operative complications and lower hospital costs.
The SPY Imaging System is United States Food and Drug Administration (“FDA”) 510(k) cleared for use for use in seven surgical specialties. The endoscopic version of SPY called PINPOINT™, combines the capabilities of SPY Imaging with high definition (“HD”) visible light visualization offered by conventional endoscopes. Our unique business model of partnering with market-leading companies to drive adoption of our fluorescence imaging technology, while building our own commercial infrastructure is the cornerstone of our corporate strategy for growth.
Novadaq Reports First Quarter 2012 Financial Results
Forward Looking Statements
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Novadaq's current beliefs as well as assumptions made by and information currently available to Novadaq and relate to, among other things, the Company’s strategy, strategic goals, research and development activities, research and clinical testing outcomes, taxes, capital expenditures, future operations, future financial position, future revenues/results, projected costs, prospects and plans and objectives of management.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings available at www.sedar.com, actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor and Media Relations
Company:
David C. Martin
Vice President, Corporate Development and Investor Relations
Novadaq Technologies Inc.
905-629-3822 ext: 218
dmartin@novadaq.com
Novadaq Reports First Quarter 2012 Financial Results
Novadaq Technologies Inc.
INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(expressed in U.S. dollars)
| | | | | | | | |
| | | As at
March 31,
2012 | | | As at
December 31,
2011 | |
ASSETS | | | | | | | | |
Current assets | | | | | | | | |
Cash and cash equivalents | | $ | 7,894,253 | | | $ | 9,633,608 | |
Accounts receivable | | �� | 2,145,413 | | | | 2,018,782 | |
Prepaid expenses and other | | | 1,508,354 | | | | 829,625 | |
Inventories | | | 2,249,449 | | | | 1,755,729 | |
| | |
Non-current assets | | | | | | | | |
Property and equipment | | | 7,500,057 | | | | 6,034,674 | |
Deferred tax assets | | | 222,546 | | | | 248,640 | |
Intangible assets | | | 1,977,681 | | | | 2,272,434 | |
| | | | | | | | |
| | |
Total Assets | | $ | 23,497,753 | | | $ | 22,793,492 | |
| | | | | | | | |
LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIENCY) | | | | | | | | |
Current liabilities | | | | | | | | |
| | |
Accounts payable and accrued liabilities | | | 4,341,377 | | | $ | 2,485,994 | |
Provisions | | | 41,620 | | | | 41,300 | |
Deferred revenue | | | 450,238 | | | | 396,859 | |
Deferred partnership fee revenue | | | 1,300,000 | | | | 1,300,000 | |
Repayable government assistance | | | 202,556 | | | | 197,760 | |
| | |
Non-current liabilities | | | | | | | | |
Deferred tax liabilities | | | 222,546 | | | | 248,640 | |
Convertible debentures | | | 4,327,830 | | | | 4,223,454 | |
Deferred revenue | | | 164,357 | | | | 188,883 | |
Deferred partnership fee revenue | | | 4,266,666 | | | | 4,591,666 | |
Repayable government assistance | | | 169,175 | | | | 214,402 | |
Shareholder warrants | | | 11,876,354 | | | | 8,278,105 | |
| | | | | | | | |
| | |
Total Liabilities | | $ | 27,362,719 | | | $ | 22,167,063 | |
| | | | | | | | |
Shareholders’ (Deficiency) Equity | | | | | | | | |
Share capital | | $ | 98,825,650 | | | $ | 98,695,023 | |
Contributed surplus | | | 6,895,159 | | | | 6,772,298 | |
Equity component of convertible debentures | | | 1,454,353 | | | | 1,454,353 | |
Deficit | | | (111,040,128 | ) | | | (106,295,245 | ) |
| | | | | | | | |
Total Shareholders’ (Deficiency) Equity | | $ | (3,864,966 | ) | | $ | 626,429 | |
| | | | | | | | |
| | |
Total Liabilities and Shareholders’ (Deficiency) Equity | | $ | 23,497,753 | | | $ | 22,793,492 | |
| | | | | | | | |
Novadaq Reports First Quarter 2012 Financial Results
Novadaq Technologies Inc.
INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
(Unaudited)
(expressed in U.S. dollars)
| | | | | | | | |
| | | For the three months ended | |
| | | March 31,
2012 | | | March 31,
2011 | |
Product sales | | $ | 3,654,045 | | | $ | 1,735,892 | |
Royalty revenue | | | 608,083 | | | | — | |
Deferred licensing revenue | | | 325,000 | | | | 200,000 | |
Service revenue | | | 180,247 | | | | 404,938 | |
| | �� | | | | | | |
Total revenues | | $ | 4,767,375 | | | $ | 2,340,830 | |
Cost of sales | | | 2,045,537 | | | | 1,257,057 | |
| | | | | | | | |
Gross margin | | $ | 2,721,838 | | | $ | 1,083,773 | |
| | | | | | | | |
| | |
Selling and distribution costs | | $ | 1,063,487 | | | $ | 1,275,219 | |
Research and development expenses | | | 1,161,731 | | | | 1,048,128 | |
Administrative expenses | | | 1,470,950 | | | | 1,112,784 | |
| | | | | | | | |
Total operating expenses | | $ | 3,696,168 | | | $ | 3,436,131 | |
| | | | | | | | |
| | |
Loss from operations before the following | | $ | (974,330 | ) | | $ | (2,352,358 | ) |
| | |
Finance costs | | $ | (172,731 | ) | | $ | (167,578 | ) |
| | |
Finance income | | | 427 | | | | 7,085 | |
| | |
Shareholder warrants revaluation adjustment | | | (3,598,249 | ) | | | 4,307 | |
| | |
Gain on investment | | | — | | | | 25,000 | |
| | | | | | | | |
Loss and comprehensive loss for the period | | $ | (4,744,883 | ) | | $ | (2,483,544 | ) |
| | | | | | | | |
Basic and diluted loss and comprehensive loss per share for the period | | $ | (0.15 | ) | | $ | (0.09 | ) |
| | | | | | | | |
Novadaq Reports First Quarter 2012 Financial Results
Novadaq Technologies Inc.
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(expressed in U.S. dollars)
| | | | | | | | |
| | | For the three months ended | |
| | | March 31,
2012 | | | March 31,
2011 | |
OPERATING ACTIVITIES | | | | | | | | |
Loss and comprehensive loss for the period | | $ | (4,744,883 | ) | | $ | (2,483,544 | ) |
Items not affecting cash | | | | | | | | |
Depreciation of property and equipment | | | 418,182 | | | | 192,210 | |
Amortization of intangible assets | | | 294,753 | | | | 235,183 | |
Stock-based compensation | | | 253,488 | | | | 205,020 | |
Finance costs, including imputed interest on convertible debentures | | | 104,376 | | | | 96,760 | |
Warrants revaluation adjustment | | | 3,598,249 | | | | (4,307 | ) |
| | | | | | | | |
| | $ | (75,835 | ) | | $ | (1,758,678 | ) |
| | | | | | | | |
Changes in non-cash working capital balances | | | | | | | | |
(Decrease) increase in deferred revenue | | $ | 40,387 | | | | 323,772 | |
(Increase) decrease in accounts receivable | | | (126,631 | ) | | | 322,895 | |
Increase in inventories | | | (493,720 | ) | | | (799,410 | ) |
Increase in accounts payable and accrued liabilities | | | 1,845,432 | | | | 627,129 | |
Decrease( increase) in prepaid expenses and other | | | (652,635 | ) | | | 438,812 | |
| | | | | | | | |
Net change in non-cash working capital balances related to operations | | $ | 612,833 | | | $ | 913,198 | |
| | | | | | | | |
(Decrease) increase in long term deferred revenue | | | (357,650 | ) | | | (239,148 | ) |
| | | | | | | | |
Cash provided by (used in) operating activities | | $ | 179,348 | | | $ | (1,084,628 | ) |
| | |
INVESTING ACTIVITIES | | | | | | | | |
Additions to property and equipment | | $ | (1,913,282 | ) | | $ | (749,265 | ) |
Disposals of property and equipment | | | 29,717 | | | | 27,409 | |
Purchase of TMR business | | | — | | | | (1,000,000 | ) |
| | | | | | | | |
Cash used in investing activities | | $ | (1,883,565 | ) | | $ | (1,721,856 | ) |
| | | | | | | | |
| | |
FINANCING ACTIVITIES | | | | | | | | |
Issuance of common shares and warrants | | | — | | | $ | 15,278,447 | |
Transaction costs of common shares and warrants | | | — | | | | (998,207 | ) |
Repayable government assistance | | $ | (40,431 | ) | | | — | |
| | | | | | | | |
Cash (used in) provided by financing activities | | $ | (40,431 | ) | | $ | 14,280,240 | |
| | | | | | | | |
| | |
Net (decrease) increase in cash and cash equivalents during the period | | $ | (1,744,648 | ) | | $ | 11,473,756 | |
Net foreign exchange difference | | | 5,293 | | | | 38,775 | |
Cash and cash equivalents at beginning of period | | | 9,633,608 | | | | 5,597,407 | |
| | | | | | | | |
Cash and cash equivalents at end of period | | $ | 7,894,253 | | | $ | 17,109,938 | |
| | | | | | | | |
